Skip to main content
. 2021 Jan 13;9(1):45. doi: 10.3390/vaccines9010045

Figure 3.

Figure 3

E2-specific antibody blocking analysis and neutralizing antibody titration in vivo. (a) CSFV E2-specific antibody blocking rate assay by IDEXX kit. (b) CAFV E2 neutralizing antibody titration in pK-15 cells. The data presented in this figure for (a,b) were calculated by two-way ANOVA analysis using GraphPad Prism 8.0 with 4 technical repeats. *, 0.05< p < 0.01; **, 0.01< p < 0.001; ***, p < 0.001.